Acerus Receives Notice of Deficiency – Withdrawal Letter from Health Canada Regarding Gynoflor Application Life Science Investing
Eton Pharmaceuticals Announces Licensing of Oral Liquid Product Candidate ET-104 Life Science Investing
Seelos Therapeutics Announces Successful Completion of its Merger with Apricus Biosciences Life Science Investing
Proteon Therapeutics Announces Publication of Results from Phase 3 PATENCY-1 Clinical Trial Life Science Investing
Neurology Publishes Study Reporting Significant Improvements in Duchenne Muscular Dystrophy Life Science Investing
Auris Medical Announces Publication of New Data Highlighting the Role of Betahistine Pharmaceutical Investing
Athersys Announces Positive Results From Its Exploratory Clinical Study of MultiStem Cell Therapy Life Science Investing
